Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The drug, which is named MariTide and delivered in a monthly injection, is some time away from being sold. The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year.
Amgen Obesity Drug Cut Weight In Closely Watched Study
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a midstage study, but fell short of the loftier expectations of some investors. Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos,
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
Amgen ( AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations. The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.
Amgen Stock Sinks On Modest Obesity Drug Results, But Retail Sentiment Remains Steady
Amgen, Inc. ($AMGN) shares nosedived in Tuesday’s pre-market session after the biopharma announced Phase-2 data for its investigational weight-loss drug MariTide. MariTide, an antibody peptide conjugate,
These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Best Buy, Rivian, NRG Energy, Kohl’s, Semtech, and More
Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...
Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock
We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this ...
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...
The Motley Fool on MSN3d
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
Eli Lilly lost the momentum it had during the first half of the year. However, the company still has plenty of ...
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund
Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter ...
ALS News Today17h
Lilly to develop ALS therapies against targets ID’d with Verge tech
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
The Motley Fool on MSN6d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly and Company: Lilly announces changes on board of directors
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?
Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...